Objective-To study whether recombinant human erythropoietin (r-hu-Epo) improves anaemia and reduces disease activity in patients with rheumatoid arthritis and anaemia of chronic disease (ACD).
(ACD).
Methods-A 52 week placebo controlled randomised double blind trial with r-hu-Epo was performed in 70 patients with active rheumatoid arthritis and ACD. Thirty four patients were treated with 240 U kg-l r-hu-Epo subcutaneously, initially three doses weekly, while 36 patients received placebo. Results-A significant increase of haemoglobin from a median of 112 to 135 g litre-' occurred in the Epo group within six weeks and could be sustained with reduced doses (median 240 U kg-' once weekly). Sustained benefit compared to placebo was also apparent by six weeks for disease activity, as indicated by the Paulus 20% response rate. Of patients in the Epo group, 32% eventually showed a Paulus 20% response, compared to 8% of the placebo group (P = 0.016). Significant differences in favour ofthe Epo group were also observed in the secondary disease activity measures Ritchie index, number of swollen joints, pain score, ESR, and patients' global assessment of disease activity. C reactive protein concentrations did not change significantly.
Conclusions-Treatment of ACD in rheumatoid arthritis with r-hu-Epo is effective in restoring normal haemoglobin levels and also exerts a beneficial effect on disease activity. Anaemia often occurs in patients with rheumatoid arthritis.' Anaemia of chronic disease (ACD) is the most important cause of anaemia in this condition.2' It is characterised by low serum iron concentrations despite normal or increased body iron stores. [5] [6] [7] The pathogenesis of ACD in rheumatoid arthritis is multifactorial. Iron retention by the mononuclear phagocyte system (MPS) and impaired iron transport to the erythroblast have been described.8 Suppression of erythropoiesis by inflammatory cytokines, such as interleukin-1 (IL-1), tumour necrosis factor a (TNF-a), and y interferon, has been shown in vitro. '-12 In addition, evidence has been provided for a relatively impaired production of erythropoietin in response to anaemia. Serum erythropoietin concentrations in ACD are lower than in other anaemic conditions'3-'" and IL-1 and TNF-a have been shown to suppress hypoxia related erythropoietin production by HepG2 and Hep3b cell line in vitro." 1 In a number of studies treatment with r-huEpo resulted in improvement of ACD in rheumatoid arthritis patients.1825 However, higher doses of human recombinant erythropoietin (r-hu-Epo) were required to maintain the haematological response than in renal disease. 26 In one open pilot study with r-hu-Epo, a decrease in both pain score and swollen and painful joint count was observed, indicating possible beneficial effects on disease activity as well.27 In the five other open and two controlled clinical studies only slight, or no, effects on disease activity were observed, although an improvement in general wellbeing was reported in several instances.2'-24 These studies were of short duration (2-24 weeks) and involved only a limited number of patients (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) . We conducted a 52 week placebo controlled randomised double blind trial with r-hu-Epo as adjuvant treatment in patients with active rheumatoid arthritis and ACD to investigate the effects of long term treatment with r-hu-Epo on haematological indices as well as on clinical and serological measures of disease activity.
Methods

PATIENTS
Patients aged 18 years or older were eligible if they met the revised American College of Rheumatology (ACR) criteria for rheumatoid arthritis28 and were classified in functional class I, II, or III.29 Active disease was required, defined as a minimum of nine swollen joints and a Ritchie score of 9. Treatment with the following disease modifying antirheumatic drugs was allowed, provided the dose was stable for three months before the start of the trial: oral gold, hydroxychloroquine, D-penicillamine, sulphasalazine, and methotrexate. Parenteral gold salts were allowed if the dose was stable for at least six months.
Patients receiving azathioprine, cyclophosphamide, or cyclosporin were excluded. Treatment with corticosteroids, equivalent to an average maximum daily dosage of 10 mg prednisone, was allowed if dosage had not been changed the last month before entry to the trial.
Anaemia of chronic disease for a minimum duration of three months had to be present in all patients. Haemoglobin concentrations below 1 17 g litre' (for both males and females) were required without signs ofvitamin and iron deficiency, blood loss, haemolysis, or other haematological disorder. Body iron stores were assessed preferably by iron staining of bone marrow smears. A semiquantitative scale was used: 0 = no stainable iron; 0 -1 = minimal to very small amount; 2 = slight small and patchy content; 3 or more = increased stainable iron. Patients with a stainable iron content of 2 or more were considered not to be iron deficient. 30 When patients did not agree with bone marrow aspiration, serum ferritin levels should be above 50 mg litre' and serum transferrin levels below 50 mmol litre-Y.3
Further exclusion criteria were: history of thromboembolic events or epileptic fits, uncontrolled hypertension, and clinically relevant impairment of kidney or liver function.
All patients gave their informed consent for the trial, which was approved by the institutional ethics committee.
TREATMENT
The study was a 52 week randomised double blinded placebo controlled parallel clinical study. Disease activity measures were assessed by the first observer (RP), who remained blinded for treatment schedules and laboratory results. Randomisation of the patients, control of adverse events and laboratory results, and administration of the study medication was done by a second independent observer (MJ).
The treatment group received r-hu-Epo (Recormon, Boehringer Mannheim) at a dose of 240 U kg-l subcutaneously ( observer's global assessment of disease activity, the Paulus response was evaluated using the other five variables. Patients had to show simultaneous improvement in four of these five variables in order to fulfil the criteria for a 20% Paulus response. Improvement was defined by a 20% decrease in the continuous variables and a 40% decrease in the patients global assessment of disease activity (1-10 scale) (or 20% in case of baseline value below 4.0).
Secondary assessments
As secondary evaluation criteria a core set of single measures of disease activity endorsed by the ACR3 was used. Besides the Ritchie index, the number of swollen joints, patients' global assessment, and Westergren ESR, this includes a pain score (1-10) and C reactive protein concentrations. Serum ferritin was assessed on every visit as the primary marker for iron status and as a guideline for iron suppletion.
STATISTICAL PROCEDURES
Data from the patient files were transferred to software packages (SPSS 5.01 and Egret) for statistical analysis. All variables were checked for their suitability for standard statistical analysis. In case of non-parametric distribution a transformation towards normality was tried. At baseline, groups were compared using Student's t test, the Mann-Whitney test, and the x' test where appropriate. The repeated measurements of continuous outcome variables in the two groups were analysed by analysis of variance for repeated measurements (MANovA) using weeks 0 (baseline), 6, 12, 24,36, and 52 as time points. The overall effect of treatment was tested for significance using the F test on the interaction between the two patient groups and the repeated measurements factor time. In case of significance, differences between the groups at individual time points were investigated with Bonferroni correction for multiple testing. Overall treatment effects on the Paulus 20% response rate were evaluated using logistic regression with random effects. Groups were compared at individual points of follow up using Fischer's exact tests.
Analysis was done on the basis of intention to treat as well as on completers. Both methods led to the same results except for slight differences in the Paulus 20% response rate.
Results of the intention to treat analysis are shown and end point differences in Paulus response described separately. However, an improvement in general wellbeing was described by most workers even in the absence of clinical improvement.2 -24 As in the present study, a decrease of ESR, but not of C reactive protein was observed in most studies.
22 2324 Thus indications for a possible effect of r-hu-Epo on disease activity were found in previous studies. A similar improvement of disease activity-as observed in the present study-has not been described before. Considerable differences in number and selection of patients, dosage of r-hu-Epo, duration of treatment, and concomitant iron supplementation, as well as disease activity measures used, could perhaps account for these differences in observed clinical responses to r-hu-Epo.
Several mechanisms can explain the beneficial effects of r-hu-Epo. Treatment with r-hu-Epo increases iron turnover, which is mobilised from storage elsewhere in the body and transferred to the bone marrow to fulfil the enhanced requirements of stimulated erythropoiesis.'6 Deposition of iron in synovial tissue was found to be increased in rheumatoid 37 38 arthritis. This has been associated with persistent joint inflammation in rheumatoid arthritis'9 since iron catalyses the generation of toxic oxygen radicals,24 stimulates DNA synthesis in synovial cells, and has an additive effect on the activity of human cytokines for proliferation of synovial cells.' Iron suppletion has been associated with exacerbation of synovial inflammation in rheumatoid arthritis patients,4' whereas iron chelators caused a rapid decrease in body iron storage and an improvement in clinical disease activity.'5 42 In the present study an equally rapid decrease in body iron stores and rheumatic disease activity was observed. Reduction of the iron availability in synovial tissue could account for the observed improvement in disease activity during r-hu-Epo treatment.
In addition to effects on iron deposition, modulating effects of r-hu-Epo on the immune system cannot be ruled out entirely. Erythropoietin has been found to regulate IgE production in vitro by T cell and monocyte dependent mechanisms.4' In renal patients treated with r-huEpo, an improvement in T cell function has been described. 44 To what extent these observations are associated with the beneficial clinical effects of r-hu-Epo in rheumatoid arthritis in the present study remains to be established. A randomised study of the effects of rhu-Epo and blood transfusion on both the immune system and clinical disease activity might be helpful in elucidating the way of action of r-hu-Epo.
The clinical use of r-hu-Epo may be limited by its expense. Furthermore, one can argue whether ACD should be treated in rheumatoid arthritis patients, as it is usually mild.4 5 However, ACD is a frequent manifestation in rheumatoid arthritis,' 4 and in our study treatment of this typically mild anaemia with r-hu-Epo had a beneficial effect. Furthermore, no side effects were observed. This might result in an important improvement of the quality of life of rheumatoid arthritis patients, which is considered to be a major aim of treatment. Therefore further research on the effects of r-hu-Epo on quality of life in relation to its costs-as compared to standard regimens-is required to elucidate the value of r-hu-Epo in the treatment of rheumatoid arthritis and ACD. Other patient groups, like anaemic patients undergoing surgery or anaemic patients starting with slow acting second line drugs, should be studied in this way as well.
In summary, our study is the first randomised placebo controlled long term study with r-huEpo in which effects on anaemia as well as on disease activity were studied extensively and adequately in a large number of patients with active rheumatic disease and anaemia of chronic disease. Rapid normalisation of Hb occurred in the majority of patients. Parallel to the response of Hb, a rapid and sustained improvement in disease activity was observed. The results of this trial suggest that r-hu-Epo might serve as a useful addition to the therapeutic armamentarium in rheumatoid arthritis patients with active disease and ACD. 
